Loading
HS-20089 is an experimental antibody-drug conjugate from Hansoh BioMedical R&D in phase 3 trials for ovarian cancer and endometrial cancer, with its target not yet stated publicly.
HS-20089 is an antibody-drug conjugate developed by Hansoh BioMedical R&D. The sponsor describes its target as B7-H4, which OnCo does not yet have a target page for. The sponsor states: HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer. ClinicalTrials.gov describes the intervention as: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatmen. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06855069 (HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer), in ovarian cancer and endometrial cancer. The largest, NCT06855069, plans to enrol 468 participants with primary completion expected 2027-03-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer. Connects to B7-H4 (VTCN1).
1.HS-20089's antibody arm binds B7-H4 (VTCN1) on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HS-20089" OR ABSTRACT:"HS-20089") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HS-20089, not a curated reading list.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.